drug · protein
MOUNJARO
updated 3mo ago/ tur-ZEP-ə-tyde /
by $LLY ELI LILLY & Co🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 6Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.
targets
Glucagon-like peptide 1 receptorGastric inhibitory polypeptide receptor
all catalysts(0)
nothing on the calendar yet
Trials studying MOUNJARO
- phase2A Study to Evaluate ALN-2232 in Participants With Obesity
- phase3A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- phase4AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
- phase3A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- phase3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
- phase3Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- phase2A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
- phase3Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
News(10)
- STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and moreSeven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 eachstat · 3d ago
- After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.fiercebiotech · 5d ago
- Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugsMedicare’s new weight loss drug program “risks creating barriers at precisely the moment when confidence in broader GLP‑1 coverage is most needed,” writes Jeffrey Millstein.stat · 5d ago
- Lilly, FDA retatrutide biologic dispute comes to a head as submission nearsA legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicin…biospace · 11d ago
- Lilly climbs, Novo falls as obesity drug battle intensifiesA research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.biopharma_dive · 11d ago
- Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the e…biospace · 11d ago
- Novo CEO sees innovation as a matter of survival amid pipeline setbacksNovo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…biospace · 11d ago
- Lilly once again beats expectations as tirzepatide accounts for 64% of revenueEli Lilly posted $23 billion in second-quarter revenues, coming in about $3 billion above analysts' estimates. Lilly also once again raised its full-year revenue guidance to between $85 billion and…endpoints · 11d ago
- ‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growthNovo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the company unveiled its second-quarter earnings, reflecting on Novo’s “roller coaster” financial journey, the pressure of navigati…fiercebiotech · 11d ago
- Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataNovo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is…fiercebiotech · 12d ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that